1-10%
Nasopharyngitis (4.3%),Hyperlipidemia (2.8%; with pioglitazone),Cough (2.4%; with metformin and sulfonylurea),Hypertriglyceridemia (2.4%; with sulfonylurea),Weight gain (2.3%; with pioglitazone),
Hypoglycemia 7.6% overall incidence, 22.9% incidence compared with placebo plus metformin and a sulfonylurea
Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone